Molecule.one is a technology company developing artificial intelligence platforms for chemical synthesis and autonomous discovery in the pharmaceutical and biotechnology sectors.
Its flagship MARIA™ platform combines frontier chemistry AI models in an agentic framework with a purpose-built microliter-scale high-throughput experimentation (HTE) laboratory and proprietary reaction datasets. This integration enables near-autonomous retrosynthesis planning, reaction optimization, compound library generation, and scalable manufacturing route discovery.
Founded in 2016 and headquartered in Warsaw, Poland, with a U.S. presence, the company operates one of the largest microliter-scale HTE facilities, having executed hundreds of thousands of reactions to train its models. It serves clients in drug discovery, fine chemicals, and related industries by delivering bespoke synthesis solutions and supporting in-house automation.
Molecule.one is privately held and venture-backed, with investors including Standard Industries. In 2025 it won the Standard Industries Chemical Innovation Challenge, resulting in a multi-year strategic partnership with W.R. Grace & Co. to advance peptide building block synthesis. The company positions itself as a leader in chemical AI, aiming to expand the synthesizable chemical space and accelerate innovation from bench to commercial scale.
Also known as Molecule One Sp. z o.o..
Multi-year partnership uses AI-driven retrosynthesis and microliter high-throughput experiments to speed scalable synthesis of peptide building blocks and relieve GLP‑1 supply-chain bottlenecks.
AI retrosynthesis platform chosen from 30+ entrants to speed molecule development and scale-up; multiple runners-up received cash prizes.
